Search

Purpose: Antihypertensive drugs are prescribed to patients with chronic kidney disease (CKD) for their cardioprotective and renoprotective effects. Nationally representative information on the use of antihypertensive drugs among CKD patients is limited. The purpose of this study was to assess the utilization patterns of antihypertensive drugs among the CKD population (stages I-IV) in the United States. Methods: We conducted a retrospective crosssectional analysis of the National Health and Nutrition Examination Survey (NHANES) panels from 2005-2006, 2007-2008, and 2009-2010. The estimated glomerular filtration rate was calculated and kidney damage was assessed to identify participants with CKD. The demographic and clinical characteristics of the participants with CKD were reported, as were the antihypertensive drugs they used. Findings: A total weighted sample of 116,231,361 participants representative of the CKD population in the United States (stages I-IV) was identified. Less than one half of the participants with CKD in the NHANES were using antihypertensive drugs. β- blockers were the most commonly used and angiotensin II receptor blockers were the least used antihypertensive agents among participants with CKD. Age (Z70 years), awareness of hypertension or diabetes, and higher stage of CKD were associated with an increased likelihood of antihypertensive drug use among participants with CKD. Implications: The results of our analyses suggest that antihypertensive drugs are underused in the CKD population, and the use of preferred agents (ie, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers) is low. Efforts should be directed toward emphasizing the importance of using antihypertensive drugs in the CKD population. [ABSTRACT FROM AUTHOR]

Background: Although long-chain ω-3 (n-3) PUFAs (LCco3PUFAs) have been linked to the prevention of some inflammatory disorders, little is known about the association between these fatty acids and incidence of asthma. Objective: The objective was to prospectively investigate the association between LCω3PUFAs and fish intake and incidence of asthma among American young adults. Design: A 20-y follow-up longitudinal analysis was conducted in a biracial cohort of 4162 Americans, aged 18-30 y, with a history of asthma at baseline in 1985. Diet was assessed by a validated interviewer-administered quantitative food-frequency questionnaire at the examinations in 1985, 1992, and 2005. Incident self-reported asthma was defined as having a physician diagnosis of asthma and/ or the use of asthma medications between 1985 and 2005. Results: During the 20-y follow-up, 446 incident cases of asthma were identified. LCco3PUFA intake was significantly inversely associated with incidence of asthma after adjustment for sociodemo- graphic, major lifestyle, and dietary confounders. The multivariable- adjusted HR for the highest quintile of LCω3PUFA intake as compared with the lowest quintile was 0.46 (95% CI: 0.33, 0.64; P-trend < 0.01). However, a higher frequency of nonfiied fish con- sumption was not significantly associated with the risk of asthma. DHA showed a greater inverse association than did EPA. The associ- ation between LCβ3PUFAs and incident asthma was not appreciably modified by sex, race, BMI, smoking status, or atopic status. Conclusion: This study showed that intakes of LCβ3PUFAs are inversely longitudinally associated with the incidence of asthma in American young adults. [ABSTRACT FROM AUTHOR]